Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients

@article{Coriat2010FeasibilityOO,
  title={Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients},
  author={Romain Coriat and Olivier Mir and Anatole Cessot and Catherine Br{\'e}zault and Stanislas Ropert and J P Durand and Wulfran Cacheux and Stanislas Chaussade and François Goldwasser},
  journal={Investigational New Drugs},
  year={2010},
  volume={30},
  pages={376-381}
}
Purpose The only drug that improves survival in hepatocellular carcinoma is sorafenib. FOLFOX-4 regimen is safe and widely used in patients with colorectal cancer, yielding interesting results with little toxicity. We conducted a retrospective study to evaluate the safety and the effectiveness of FOLFOX-4 in cirrhotic or liver transplanted patients with hepatocellular carcinoma ineligible for sorafenib. Methods Thirty seven patients were enrolled in the study. The medical record of either… CONTINUE READING
9 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Real Progression Free Survival

  • JM Llovet, J Bruix, +8 authors M Sole
  • Invest New Drugs
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…